Cantor Fitzgerald analyst Josh Schimmer initiated coverage of Aardvark Therapeutics (AARD) with an Overweight rating and $50 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD: